The stock of Insys Therapeutics Inc (NASDAQ:INSY) is a huge mover today! The stock decreased 2.40% or $0.29 during the last trading session, hitting $11.79. About 895,378 shares traded hands or 10.50% up from the average. Insys Therapeutics Inc (NASDAQ:INSY) has declined 32.55% since February 29, 2016 and is downtrending. It has underperformed by 42.98% the S&P500.
The move comes after 7 months negative chart setup for the $801.64 million company. It was reported on Oct, 1 by Barchart.com. We have $10.73 PT which if reached, will make NASDAQ:INSY worth $72.15M less.
Analysts await Insys Therapeutics Inc (NASDAQ:INSY) to report earnings on November, 3. INSY’s profit will be $4.08M for 49.13 P/E if the $0.06 EPS becomes a reality. After $0.06 actual earnings per share reported by Insys Therapeutics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Insys Therapeutics Inc (NASDAQ:INSY) Ratings Coverage
Out of 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Insys Therapeutics has been the topic of 8 analyst reports since August 4, 2015 according to StockzIntelligence Inc. Jefferies maintained the shares of INSY in a report on Thursday, August 4 with “Buy” rating. JMP Securities maintained it with “Market Outperform” rating and $30 target price in Wednesday, March 9 report. The firm earned “Buy” rating on Wednesday, February 24 by Jefferies. The firm has “Buy” rating by Zacks given on Friday, August 14. The firm has “Hold” rating by Oppenheimer given on Tuesday, August 4. The stock of Insys Therapeutics Inc (NASDAQ:INSY) earned “Buy” rating by Jefferies on Tuesday, April 12. On Thursday, April 14 the stock rating was initiated by Janney Capital with “Buy”. RBC Capital Markets maintained Insys Therapeutics Inc (NASDAQ:INSY) on Thursday, September 22 with “Outperform” rating.
According to Zacks Investment Research, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.”
Insitutional Activity: The institutional sentiment decreased to 0.7 in Q2 2016. Its down 0.36, from 1.06 in 2016Q1. The ratio worsened, as 22 funds sold all Insys Therapeutics Inc shares owned while 42 reduced positions. 13 funds bought stakes while 32 increased positions. They now own 31.30 million shares or 9.76% less from 34.69 million shares in 2016Q1.
Blackrock Invest Management Limited Liability reported 113,933 shares or 0% of all its holdings. Gam Ag last reported 0.02% of its portfolio in the stock. Nationwide Fund Advisors has invested 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). The New York-based Tower Rech Cap Ltd Com (Trc) has invested 0% in Insys Therapeutics Inc (NASDAQ:INSY). Commerzbank Aktiengesellschaft Fi accumulated 0% or 31,941 shares. Tci Wealth Advsrs has invested 0.03% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Panagora Asset Management holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 1,359 shares. Jpmorgan Chase And has invested 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Rhumbline Advisers reported 28,140 shares or 0% of all its holdings. Zurcher Kantonalbank (Zurich Cantonalbank) has 697 shares for 0% of their US portfolio. Adage Prtnrs Grp Ltd Liability Co has 0.01% invested in the company for 275,000 shares. Blackrock Japan Limited has 1,400 shares for 0% of their US portfolio. Orbimed Advsr Limited Co reported 4.69M shares or 0.63% of all its holdings. Victory Incorporated has 0% invested in the company for 3,313 shares. Geode Cap Mngmt Limited Liability Corporation last reported 182,001 shares in the company.
Insider Transactions: Since May 11, 2016, the stock had 2 buys, and 4 selling transactions for $170,592 net activity. JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989 also bought $641,827 worth of Insys Therapeutics Inc (NASDAQ:INSY) on Wednesday, May 11. $270,300 worth of Insys Therapeutics Inc (NASDAQ:INSY) was sold by STANLEY THEODORE H. BRENNAN DANIEL sold 5,781 shares worth $110,752. $276,900 worth of Insys Therapeutics Inc (NASDAQ:INSY) was sold by FOURTEAU PATRICK on Thursday, August 11.
More important recent Insys Therapeutics Inc (NASDAQ:INSY) news were published by: Fool.com which released: “Here’s Why Insys Therapeutics Inc. Fell 14.3% in April” on May 10, 2016, also Globenewswire.com published article titled: “Insys Therapeutics Announces CEO Succession Plan”, Businessinsider.com published: “A pharmaceutical company is fighting marijuana legalization because it would …” on September 13, 2016. More interesting news about Insys Therapeutics Inc (NASDAQ:INSY) was released by: Finance.Yahoo.com and their article: “Insys Therapeutics, Inc. to Present at Morgan Stanley Global Healthcare Conference” with publication date: September 01, 2016.
INSY Company Profile
Insys Therapeutics, Inc., incorporated on June 15, 1990, is a commercial-stage specialty pharmaceutical company. The Firm develops and commercializes supportive care products. Subsys is the Company’s marketed product. Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and is a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Firm markets Subsys through its field sales force focused on supportive care physicians in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.